Organization profile

Organisation Profile

We are studying the role of prolyl oligopeptidase (PREP, formerly known as POP) on disease progression and neuronal toxicity in neurodegenerative disorders with protein aggregation. These disorders involve several serious diseases such as Alzheimer’s and Parkinson’s diseases, and several more rare neurodegenerative conditions. Based on PREP inhibitors, we are developing novel and disease-modifying drug therapies to stop the neuronal death in Alzheimer's and Parkinson's diseases.

Read more on our website

International and National Collaboration Publications and projects within past five years.

Projects

Publications

Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent

Serfozo, P., Wysocki, J., Gulua, G., Schulze, A., Ye, M., Liu, P., Jin, J., Bader, M., Myöhänen, T., Garcia Horsman, J. A. & Batlle, D., Jan 2020, In : Hypertension. 75, 1, p. 173-182 10 p.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File

Missing Selectivity of Targeted 4 beta-Phorbol Prodrugs Expected to be Potential Chemotherapeutics

Tarvainen, I., Zimmermann, T., Heinonen, P., Jäntti, M. H., Yli-Kauhaluoma, J., Talman, V., Franzyk, H., Tuominen, R. K. & Christensen, S. B., 14 May 2020, In : ACS Medicinal Chemistry Letters. 11, 5, p. 671-677 7 p.

Research output: Contribution to journalArticleScientificpeer-review

Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A

Svarcbahs, R., Jäntti, M., Kilpeläinen, T., Julku, U., Urvas, L., Kivioja, S., Norrbacka, S. & Myöhänen, T., Jan 2020, In : Pharmacological Research. 151, 16 p., 104558.

Research output: Contribution to journalArticleScientificpeer-review

The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy

Kilpeläinen, T. P., Hellinen, L., Vrijdag, J., Yan, X., Svarcbahs, R., Vellonen, K-S., Lambeir, A-M., Huttunen, H., Urtti, A., Wallen, E. A. A. & Myohanen, T. T., Aug 2020, In : Biomedicine & Pharmacotherapy. 128, 10 p., 110253.

Research output: Contribution to journalArticleScientificpeer-review

Open Access
File
Open Access
File

Activities

Career as an academic PI

Timo Myöhänen (Speaker)

7 Jun 2019

Activity: Talk or presentation typesInvited talk

FM Johanna Viiri vastaväittöjä

Timo Myöhänen (Supervisor)

9 Aug 2019

Activity: Examination typesOpponent of doctoral dissertation

Prolyl oligopeptidase on alpha-synuclein aggregation

Timo Myöhänen (Speaker)

26 Feb 2019

Activity: Talk or presentation typesInvited talk

WCP2018, 18th World Congress of Basic and Clinical Pharmacology

Ulrika Julku (Attendee)

1 Jul 20186 Jul 2018

Activity: Participating in or organising an event typesOrganisation and participation in conferences, workshops, courses, seminars

The Impact of Prolyl Oligopeptidase Inhibitors on Alpha-Synuclein Aggregation

Timo Myöhänen (Speaker)

25 Apr 2018

Activity: Talk or presentation typesInvited talk